SynthesisNeurosurgical review2026
Anticoagulant and antiplatelet management in geriatric patients with chronic subdural hematoma: A systematic review.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLimited research has addressed how to optimally balance the risk of bleeding and thrombosis while selecting the most effective treatment strategy for chronic subdural hematoma (CSDH) in elderly patients undergoing anticoagulant (AC) or antiplatelet (AP) therapy at the time of diagnosis.
methodsWe searched for studies published between January 2017 and January 2025 in PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane systematic review registries involving older adults diagnosed with CSDH who are receiving AC or AP therapy.
resultsTen studies comprising a total of 3,962 patients were included in the final analysis, with mean ages ranging from 72 to 84.4 years. Preoperative antithrombotic (AT) therapy was not significantly associated with postoperative recurrence of CSDH; however, the use of multiple AT agents may increase the risk of recurrence and the need for reoperation. Current evidence does not support a correlation between the duration of preoperative drug withdrawal and postoperative recurrence. Four studies reported that the majority of patients resumed AT therapy within two weeks postoperatively, although the optimal timing for the resumption of AP and AC therapy remains uncertain. Prolonged discontinuation or delayed resumption of AT therapy appears to increase the risk of thromboembolic events, whereas early resumption may mitigate this risk without significantly increasing the recurrence rate.
conclusionAntithrombotic therapy did not significantly increase the risk of postoperative recurrence or reoperation in older patients with CSDH, and the duration of preoperative drug withdrawal was not associated with clinical outcomes. In the absence of clear contraindications or high-risk factors, AT therapy should be resumed as early as possible, as prolonged discontinuation may elevate the risk of thromboembolic events. Further studies are warranted to determine the optimal timing for the postoperative resumption of AC and AP therapy respectively.
Indexed as
Identifiers
41535446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.